- Oops!Something went wrong.Please try again later.
Annovis Bio, Inc. was one of the sponsors for the Benzinga Global Small-Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
Seeing someone we love going through a degenerative disease is painful and takes a tremendous toll on the people around them as they witness their loved one recede into darkness, often with disturbing personality changes. The impact on patients’ quality of life makes everyone who has been touched in one way or another with this disease wonder what we can do differently to prevent and preserve what some consider the dignity of living.
Roughly 5.8 million people in the U.S. and 44 million people worldwide are estimated to suffer from Alzheimer's disease (AD), most of them age 65 and older. Unfortunately, nothing has changed in the past 23 years. From 1998 to 2018, there were over 500 failed attempts at developing Alzheimer's drugs, primarily focused on the amyloid plaque, and currently, there haven’t been new treatments approved.
Alzheimer's is a type of dementia that affects memory, thinking, and behavior. The disease is an irreversible, progressive brain disorder that slowly destroys different skills, and eventually the ability to carry out the simplest tasks.
According to the World Health Organization (WHO), Alzheimer's disease is the most common form of dementia and may contribute to 60%–70% of cases. It is considered among the top 10 causes of death worldwide, and it ranks 3rd in the Americas and Europe. Additionally, 65% of deaths from Alzheimer’s and other forms of dementia are women.
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases, understands the concerns of those who suffer from these diseases and the need for a novel approach. This what you need to know.
There is no curative treatment for AD, and there are only a few approved treatments to treat its symptoms. The potential market for these unmet needs are in the multibillions of dollars and growing.
The company’s approach intends to stop Alzheimer’s and Parkinson’s with its drug treatment ANVS401. The drug improves axonal transport and recovers the affected function.
Currently, ANVS401 completed Phase 2 of clinical trials and will provide validation to move to Phase 3 trials. Annovis’ pipeline consists of 3 drugs for chronic neurodegeneration:
ANVS 401: Lead compound for Alzheimer’s disease (AD, its orphan indication Alzheimer’s disease and dementia in Down syndrome (AD-DS) and PD.
ANVS 405: To treat acute neurodegeneration – traumatic brain injury (TBI) and strokes
ANVS 301: For advanced Alzheimer's disease
Lead candidate ANVS 401 inhibits the translation of more than one neurotoxic protein, unlike most failed phase 3 trials, which only target 1 protein.
ANVS 401 lowers neurotoxic proteins, improves axonal transport, increases synaptic transmission, lowers inflammation, protects nerve cells from dying, and by keeping nerve cells alive improves cognitive and motor functions.
ANVS401 and ANVS405 can work in chronic and acute indications because nerve cells die from these diseases’ same mechanism. ANVS401 and ANVS405 stop the toxic cascade leading to nerve cell death.
Annovis is conducting two Phase 2 studies to show in both AD and PD patient populations that what was demonstrated in animals can be reproduced in humans and that ANVS401 protects the nerve cells from dying, and by doing so preserves the associated function.
Annovis Recent Developments
The company is pursuing a tremendous addressable market that needs more effective and safe treatment options, especially with the emotional impact beyond the patient. The company comprises top scientists and professionals who understand the importance of giving something palpable to the medical world. These are a few highlights that we think you should take into account:
ANVS has 2 ongoing double-blind, placebo-controlled Phase 2 trials: 1 in AD patients and 1 in both AD and PD patients, with preliminary data expected in Q1 2021.
Multiple animal studies showed that ANVS401 improved the affected function.
Annovis announced on Feb 4, 2021, that the European Patent Office (EPO) granted the company's patent to treat acute nerve and brain injuries by administering ANVS405 after an injury.
The USPTO approved the Company's first PD patent (US 10,383,851) in August 2019. The EPO approved Annovis Bio's first AD patent (EP 2683242) on March 12, 2020. The EPO approved Annovis Bio's first acute patent (EP 3334425B1), which provides intellectual property protections through 2036, on December 16, 2020.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.